Cargando…

Brain metastases in the elderly – Impact of residual tumor volume on overall survival

BACKGROUND: Due to demographic changes and an increased incidence of cancer with age, the number of patients with brain metastases (BMs) constantly increases, especially among the elderly. Novel systemic therapies, such as immunotherapy, have led to improved survival in recent years, but intracrania...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumgart, Lea, Aftahy, Amir Kaywan, Anetsberger, Aida, Thunstedt, Dennis, Wiestler, Benedikt, Bernhardt, Denise, Combs, Stephanie E., Meyer, Bernhard, Meyer, Hanno S., Gempt, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110925/
https://www.ncbi.nlm.nih.gov/pubmed/37081991
http://dx.doi.org/10.3389/fonc.2023.1149628
_version_ 1785027348492451840
author Baumgart, Lea
Aftahy, Amir Kaywan
Anetsberger, Aida
Thunstedt, Dennis
Wiestler, Benedikt
Bernhardt, Denise
Combs, Stephanie E.
Meyer, Bernhard
Meyer, Hanno S.
Gempt, Jens
author_facet Baumgart, Lea
Aftahy, Amir Kaywan
Anetsberger, Aida
Thunstedt, Dennis
Wiestler, Benedikt
Bernhardt, Denise
Combs, Stephanie E.
Meyer, Bernhard
Meyer, Hanno S.
Gempt, Jens
author_sort Baumgart, Lea
collection PubMed
description BACKGROUND: Due to demographic changes and an increased incidence of cancer with age, the number of patients with brain metastases (BMs) constantly increases, especially among the elderly. Novel systemic therapies, such as immunotherapy, have led to improved survival in recent years, but intracranial tumor progression may occur independently of a systemically effective therapy. Despite the growing number of geriatric patients, they are often overlooked in clinical trials, and there is no consensus on the impact of BM resection on survival. OBJECTIVES: The aim of this study was to analyze the impact of resection and residual tumor volume on clinical outcome and overall survival (OS) in elderly patients suffering from BM. METHODS: Patients ≥ 75 years who had surgery for BM between April 2007 and January 2020 were retrospectively included. Residual tumor burden (RTB) was determined by segmentation of early postoperative brain MRI (72 h). Contrast-enhancing tumor subvolumes were segmented manually. “Postoperative tumor volume” refers to the targeted BMs. Impact of preoperative Karnofsky performance status scale (KPSS), age, sex and RTB on OS was analyzed. Survival analyses were performed using Kaplan-Meier estimates for the univariate analysis and the Cox regression proportional hazards model for the multivariate analysis. RESULTS: One hundred and one patients were included. Median age at surgery was 78 years (IQR 76-81). Sixty-two patients (61%) had a single BM; 16 patients (16%) had two BMs; 13 patients (13%) had three BMs; and 10 patients (10%) had more than three BMs. Median preoperative tumor burden was 10.3 cm(3) (IQR 5–25 cm(3)), and postoperative tumor burden was 0 cm(3) (IQR 0–1.1 cm(3)). Complete cytoreduction (RTB = 0) was achieved in 52 patients (52%). Complete resection of the targeted metastases was achieved in 78 patients (78%). Median OS was 7 months (IQR 2–11). In univariate analysis, high preoperative KPSS (HR 0.986, 95% CI 0.973–0.998, p = 0.026) and small postoperative tumor burden (HR 1.025, 95% CI 1.002–1.047, p = 0.029) were significantly associated with prolonged OS. Patients with RTB = 0 survived significantly longer than those with residual tumor did (12 [IQR 5–19] vs. 5 [IQR 3–7] months, p = 0.007). Furthermore, prolongation of survival was significantly associated with surgery in patients with favorable KPSS, with an adjusted HR of 0.986 (p = 0.026). However, there were no significances regarding age. CONCLUSIONS: RTB is a strong predictor for prolonged OS, regardless of age or cancer type. Postoperative MRI should confirm the extent of resection, as intraoperative estimates do not warrant a complete resection. It is crucial to aim for maximal cytoreduction to achieve the best long-term outcomes for these patients, despite the fact the patients are advanced in age.
format Online
Article
Text
id pubmed-10110925
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101109252023-04-19 Brain metastases in the elderly – Impact of residual tumor volume on overall survival Baumgart, Lea Aftahy, Amir Kaywan Anetsberger, Aida Thunstedt, Dennis Wiestler, Benedikt Bernhardt, Denise Combs, Stephanie E. Meyer, Bernhard Meyer, Hanno S. Gempt, Jens Front Oncol Oncology BACKGROUND: Due to demographic changes and an increased incidence of cancer with age, the number of patients with brain metastases (BMs) constantly increases, especially among the elderly. Novel systemic therapies, such as immunotherapy, have led to improved survival in recent years, but intracranial tumor progression may occur independently of a systemically effective therapy. Despite the growing number of geriatric patients, they are often overlooked in clinical trials, and there is no consensus on the impact of BM resection on survival. OBJECTIVES: The aim of this study was to analyze the impact of resection and residual tumor volume on clinical outcome and overall survival (OS) in elderly patients suffering from BM. METHODS: Patients ≥ 75 years who had surgery for BM between April 2007 and January 2020 were retrospectively included. Residual tumor burden (RTB) was determined by segmentation of early postoperative brain MRI (72 h). Contrast-enhancing tumor subvolumes were segmented manually. “Postoperative tumor volume” refers to the targeted BMs. Impact of preoperative Karnofsky performance status scale (KPSS), age, sex and RTB on OS was analyzed. Survival analyses were performed using Kaplan-Meier estimates for the univariate analysis and the Cox regression proportional hazards model for the multivariate analysis. RESULTS: One hundred and one patients were included. Median age at surgery was 78 years (IQR 76-81). Sixty-two patients (61%) had a single BM; 16 patients (16%) had two BMs; 13 patients (13%) had three BMs; and 10 patients (10%) had more than three BMs. Median preoperative tumor burden was 10.3 cm(3) (IQR 5–25 cm(3)), and postoperative tumor burden was 0 cm(3) (IQR 0–1.1 cm(3)). Complete cytoreduction (RTB = 0) was achieved in 52 patients (52%). Complete resection of the targeted metastases was achieved in 78 patients (78%). Median OS was 7 months (IQR 2–11). In univariate analysis, high preoperative KPSS (HR 0.986, 95% CI 0.973–0.998, p = 0.026) and small postoperative tumor burden (HR 1.025, 95% CI 1.002–1.047, p = 0.029) were significantly associated with prolonged OS. Patients with RTB = 0 survived significantly longer than those with residual tumor did (12 [IQR 5–19] vs. 5 [IQR 3–7] months, p = 0.007). Furthermore, prolongation of survival was significantly associated with surgery in patients with favorable KPSS, with an adjusted HR of 0.986 (p = 0.026). However, there were no significances regarding age. CONCLUSIONS: RTB is a strong predictor for prolonged OS, regardless of age or cancer type. Postoperative MRI should confirm the extent of resection, as intraoperative estimates do not warrant a complete resection. It is crucial to aim for maximal cytoreduction to achieve the best long-term outcomes for these patients, despite the fact the patients are advanced in age. Frontiers Media S.A. 2023-04-04 /pmc/articles/PMC10110925/ /pubmed/37081991 http://dx.doi.org/10.3389/fonc.2023.1149628 Text en Copyright © 2023 Baumgart, Aftahy, Anetsberger, Thunstedt, Wiestler, Bernhardt, Combs, Meyer, Meyer and Gempt https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Baumgart, Lea
Aftahy, Amir Kaywan
Anetsberger, Aida
Thunstedt, Dennis
Wiestler, Benedikt
Bernhardt, Denise
Combs, Stephanie E.
Meyer, Bernhard
Meyer, Hanno S.
Gempt, Jens
Brain metastases in the elderly – Impact of residual tumor volume on overall survival
title Brain metastases in the elderly – Impact of residual tumor volume on overall survival
title_full Brain metastases in the elderly – Impact of residual tumor volume on overall survival
title_fullStr Brain metastases in the elderly – Impact of residual tumor volume on overall survival
title_full_unstemmed Brain metastases in the elderly – Impact of residual tumor volume on overall survival
title_short Brain metastases in the elderly – Impact of residual tumor volume on overall survival
title_sort brain metastases in the elderly – impact of residual tumor volume on overall survival
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110925/
https://www.ncbi.nlm.nih.gov/pubmed/37081991
http://dx.doi.org/10.3389/fonc.2023.1149628
work_keys_str_mv AT baumgartlea brainmetastasesintheelderlyimpactofresidualtumorvolumeonoverallsurvival
AT aftahyamirkaywan brainmetastasesintheelderlyimpactofresidualtumorvolumeonoverallsurvival
AT anetsbergeraida brainmetastasesintheelderlyimpactofresidualtumorvolumeonoverallsurvival
AT thunstedtdennis brainmetastasesintheelderlyimpactofresidualtumorvolumeonoverallsurvival
AT wiestlerbenedikt brainmetastasesintheelderlyimpactofresidualtumorvolumeonoverallsurvival
AT bernhardtdenise brainmetastasesintheelderlyimpactofresidualtumorvolumeonoverallsurvival
AT combsstephaniee brainmetastasesintheelderlyimpactofresidualtumorvolumeonoverallsurvival
AT meyerbernhard brainmetastasesintheelderlyimpactofresidualtumorvolumeonoverallsurvival
AT meyerhannos brainmetastasesintheelderlyimpactofresidualtumorvolumeonoverallsurvival
AT gemptjens brainmetastasesintheelderlyimpactofresidualtumorvolumeonoverallsurvival